Oasmia Pharmaceutical AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.08.19	Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs (GlobeNewswire)
02.08.19	Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs (GlobeNewswire)
31.07.19	New number of shares and votes in Oasmia Pharmaceutical AB (publ) (GlobeNewswire)
09.07.19	Oasmia discontinues cooperation with former executive chairman (GlobeNewswire)
05.07.19	Oasmia and Arwidsro have solved outstanding balances and Arwidsro increases its investment in Oasmia (GlobeNewswire)
04.07.19	Oasmia appoints Business Advisory Board (GlobeNewswire)
02.07.19	Oasmia appoints new CMO (GlobeNewswire)
28.06.19	The Board of Oasmia has decided to report certain transactions to the Swedish Economic Crime Authority and to appoint a special examiner (GlobeNewswire)
28.06.19	Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2018 – April 30, 2019 (GlobeNewswire)
28.06.19	Oasmia announces change of CEO (GlobeNewswire)
26.06.19	Oasmia presents full-year report and status in the Board's review through audiocast on June 28 (GlobeNewswire)
25.06.19	Two studies finalized in Oasmia Pharmaceutical’s Docecal programme (GlobeNewswire)
15.05.19	Oasmia postpones the release of the Q4 and year-end report to 28 June (GlobeNewswire)
10.04.19	Oasmia expands the Management Team (GlobeNewswire)
03.04.19	Short report of the status of the review in Oasmia (GlobeNewswire)
29.03.19	Increase in the number of shares and votes in Oasmia Pharmaceutical AB (publ) (GlobeNewswire)
28.03.19	The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal ”Advances in Therapy”. (GlobeNewswire)
26.03.19	Notification from Oasmia Pharmaceutical AB (GlobeNewswire)
26.03.19	CFO of Oasmia, Anders Blom has resigned (GlobeNewswire)
25.03.19	Oasmia Pharmaceutical AB receives positive opinion from the European Medicines Agency to add efficacy data to the approved Apealea® product information (GlobeNewswire)
21.03.19	New Board starts reviewing the situation in Oasmia (GlobeNewswire)
19.03.19	Oasmia Pharmaceutical AB (publ): Press release from the extraordinary general meeting 19 March 2019 (GlobeNewswire)
18.03.19	Oasmia announces a prospectus regarding admission to trading of new shares (GlobeNewswire)
04.03.19	Oasmia has completed a directed share issue of approximately 165 MSEK (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Oasmia Pharmaceutical AB

Aktien Top/Flop

Meistgelesene Nachrichten